Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. (Q45970166)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. |
scientific article |
Statements
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab (English)
Erik Stroes
David Colquhoun
David Sullivan
Fernando Civeira
Robert S Rosenson
Eric Bruckert
Leslie Cho
Ricardo Dent
Beat Knusel
Allen Xue
Scott M Wasserman
Michael Rocco
GAUSS-2 Investigators